|
Home > Offers to Sell > Chemicals & Plastics > Pharmaceutical Chemicals > Pharmaceutical Intermediates
Contact: |
Bella Yang |
Company: |
HJ Tech Co.,Ltd. |
|
No.25 Huifeng Road |
|
Shijiazhuang 050000 |
|
China |
Phone: |
8617039595306 |
E-Mail: |
|
|
|
Date/Time: |
3/18/24 15:40 GMT |
|
|
Injection GLP-1 Liraglutide Tirzepatide 15mg 10mg Gip CAS 910463-68-2
Product name tirzepatide Other name Tirzepatide;GIP\GLP-1;Tirzepatide (LY3298176);Trizepatide;Gip\GLP-1 Tirzepatide Ly3298176 Peptide;Tilposide;Tirzepatide(GLP-1);terzapiti , de CAS NO 1078-21-3 Molecular formula / Molecular weight / Assay 99% Appearance White Powder Usage Tirzepatide can be used as a single therapy (on its own) or with other diabetes medicines, including sulfonylureas, SGLT2 inhibitors or metformin.
Tirzepatide has a similar sequence to semaglutide, and the lys side chain in the sequence has PEG modification, which is the functional group of the polypeptide, and can increase the water solubility of the sequence. The main physiological function of Tirzepatide is glucose-dependent nutrition polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor double agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage. Semaglutide CAS No.910463-68-2 Tirzepatide CAS:2023788-19-2 Retatrutide CAS No.:2381089-83-2 Liraglutide CAS No.:204656-20-2 Cagrilintide AOD9604(HGH Frag) Selank Semax SS31 PT141 Epithalon Tesamor , elin Thymosin alpha 1 MOTS-C Thymulin LL-37 Oxytocin PE , G-MGF DSIP Hexarelin Sermorelin MGF Triptorelin CJC-1295 NO DAC (MOD GRF 1-29) CJC-1295 DAC GHRP-2 GHRP-6 MT2 (Melanotan II) MT1 (Melanotan 1) HGH IGF-1 LR3 HCG HMG BPC 157 TB500 Ipamorelin HGH Fragment 176-191 dihexa PMK ethyl glycidate CAS No: 28578-16-7 1,4-Butanediol BDO CAS No.:110-63-4
Whatsapp/Telegram/Signal::+86 17039595306 Email:youngpeptide@gmail.com
Minimum Order: 10 grams
Click to Enlarge
SOURCE: Import-Export Bulletin Board (https://www.imexbb.com/)
Post an Offer to Sell
© 1996-2010 IMEXBB.com. All rights reserved.
|
|